Overview

Efficacy of Sirolimus-Based, Steroid Avoidance Immunosuppression African Americans

Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
African Americans receiving a kidney transplant are considered at high risk for early rejection of their transplanted kidney and require more immunosuppression to maintain their kidney transplant function. This increase in immunosuppression puts this group at risk for drug-related toxicities and complications such as post-transplant diabetes. This study will evaluate: 1. Whether a sirolimus based steroid avoidance regimen in African Americans may decrease the risks of drug-related toxicities, 2. Decreased rates of metabolic complications such as post-transplant diabetes, 3. The effect of Sirolimus plus a reduced dose cyclosporine on renal allograft function.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University of Michigan
Collaborator:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Everolimus
Sirolimus